Matches in DBpedia 2014 for { <http://dbpedia.org/resource/AP26113> ?p ?o. }
Showing items 1 to 24 of
24
with 100 items per page.
- AP26113 abstract "AP26113 is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc. AP26113 has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). This compound targets a unique genetic feature of cancer cells and ARIAD has begun a Phase 1/2 clinical trial of AP26113 based on patients’ molecular diagnoses in September 2011. ALK was first identified as a chromosomal rearrangement in anaplastic large cell lymphoma (ALCL). Genetic studies indicate that abnormal expression of ALK is a key driver of certain types of non-small cell lung cancer (NSCLC) and neuroblastomas, as well as ALCL. Since ALK is generally not expressed in normal adult tissues, it represents a highly promising molecular target for cancer therapy.Epidermal growth factor receptor (EGFR) is another validated target in NSCLC. Additionally, the T790M “gatekeeper” mutation is linked in approximately 50 percent of patients who grow resistant to first-generation EGFR inhibitors. While second-generation EGFR inhibitors are in development, clinical efficacy has been limited due to toxicity thought to be associated with inhibiting the native (endogenous or unmutated) EGFR. A therapy designed to target EGFR, the T790M mutation but avoiding inhibition of native EGFR is another promising molecular target for cancer therapy.".
- AP26113 thumbnail AP26113.svg?width=300.
- AP26113 wikiPageID "32614566".
- AP26113 wikiPageRevisionID "597096579".
- AP26113 hasPhotoCollection AP26113.
- AP26113 imagefile "AP26113.svg".
- AP26113 imagesize "200".
- AP26113 subject Category:Experimental_cancer_drugs.
- AP26113 subject Category:Phosphine_oxides.
- AP26113 subject Category:Piperidines.
- AP26113 subject Category:Protein_kinase_inhibitors.
- AP26113 subject Category:Pyrimidines.
- AP26113 type ChemicalCompound.
- AP26113 type ChemicalSubstance.
- AP26113 type ChemicalObject.
- AP26113 type Thing.
- AP26113 comment "AP26113 is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc. AP26113 has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). This compound targets a unique genetic feature of cancer cells and ARIAD has begun a Phase 1/2 clinical trial of AP26113 based on patients’ molecular diagnoses in September 2011.".
- AP26113 label "AP26113".
- AP26113 sameAs m.0h1ckcz.
- AP26113 sameAs Q4653190.
- AP26113 sameAs Q4653190.
- AP26113 wasDerivedFrom AP26113?oldid=597096579.
- AP26113 depiction AP26113.svg.
- AP26113 isPrimaryTopicOf AP26113.
